BioPharma Credit announced that, together with BioPharma Credit Investments V, it has entered into a definitive senior secured loan agreement with BioCryst Pharmaceuticals, Inc. The company will invest up to US$180.0m and BioPharma-V will invest up to an additional US$270m in parallel, with the company acting as collateral agent. Based in the US, BioCryst is a publicly traded biopharmaceutical company with a current market capitalisation of US$1.6bn.
BioCryst currently markets ORLADEYO® (berotralstat), a treatment to prevent attacks of hereditary angioedema in adults and children 12 years of age and older. ORLADEYO® was approved in the US in December 2020 and received approvals in the European Union, Japan, the United Arab Emirates and the United Kingdom during 2021. BioCryst reported ORLADEYO® net sales of US$251.6m for 2022, a greater than 100% increase from 2021.
BPCR : BioPharma Credit funding BioCryst